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Abstract 
Background: Genomic discoveries in the era of precision medicine hold the promise for tailoring 
healthcare, symptom management, and research efforts including targeting rare and common 
diseases through the identification and implementation of genomic–based risk assessment, 
treatment, and management. However, the translation of these discoveries into tangible benefits 
for the health of individuals, families, and the public is evolving.  
Purpose:In this article, members of the Genetics Expert Panel identify opportunities for action to 
increase advanced practice nursing and research contributions toward improving genomic 
health for all individuals and populations.  
Discussion: Identified opportunities are within the areas of: bolstering genomic focused 
advanced practice registered nurse practice, research and education efforts; deriving new 
knowledge about disease biology, risk assessment, treatment efficacy, drug safety and self-
management; improving resources and systems that combine genomic information with other 
healthcare data; and advocating for patient and family benefits and equitable access to genomic 
healthcare resources. 
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Highlights 
• APRNs use genomic knowledge in risk assessment, treatment and management plans.  
• Nurse scientists need knowledge of genomic analysis, methods, and applications.  
• Nursing leaders can influence the development and implementation of genomic data. 
• APRNs provide genomic-based care and advocate for personalized healthcare for all.   
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Introduction and Problem Identification 
The promise of personalized medicine, with its focus on individual characteristics, 
including genetic factors, has inspired the healthcare community to incorporate new and 
evolving technologies into routine care and optimize their use, while adhering to ethical 
mandates of clinical practice. This represents a paradigm shift from genetics and genomics 
regarded as a “special interest addressing rare diseases, to the use of genetic information in all 
aspects of health care” (Wilson & Nicholls, 2015, p.10).  
The recently announced U.S.A. Precision Medicine Initiative aims at discovering the right 
treatment, for the right patient, at the right time, as well as discovery of factors contributing to or 
protecting from common and complex diseases (The White House, 2015). The community of 
nurse scientists and advanced practice registered nurses (APRN) must be prepared to engage 
in practice and research that will incorporate genomics and contribute to precision medicine in 
many diverse areas. Nurses must also advocate for patients’ rights regarding recruitment and 
consent to participating in genomic-related research, as well as use of personal genomic health 
information for research purposes that is consistent with individual preferences.  
Nurses, including ethnic minority nurses, are essential members of the interdisciplinary 
healthcare team who must also be prepared to use genomic information for guiding the right 
diagnosis and treatment in clinical practice (Coleman et al., 2014). As a fundamental nursing 
role, this will entail educating individuals, patients and families regarding the implications of 
genomics and how genomic findings and future advancements may guide and impact health 
care treatment, self-management choices, and decision-making. However, it is critical that these 
opportunities be extended to all including the underserved and minorities, and not limited to 
those with access, education, and resources to benefit from genomic healthcare. To ensure that 
personalized medicine will be applicable to all individuals within our diverse American 
population and reduce health disparities, nurse leaders must continue to engage inclusive 
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perspectives when incorporating genomics in research, clinical activities and policy measures. 
This will also entail facilitating the integration of genomic discoveries into healthcare while 
maintaining protections for individual and family privacy and health choices. 
Genomic discoveries are rapidly advancing from characterizing the molecular structure 
of genomes and understanding disease biology (Green, Guyer, & National Human Genome 
Research Institute, 2011) to translation of discoveries to inform clinical decisions for individuals, 
families, and communities at risk for conditions with significant genetic components. For 
example, the advent of genomic testing (e.g., Oncotype DX®) for various forms of cancer, such 
as breast, prostate, and colon, has made possible personalized predictions about 
responsiveness to chemotherapy and the risk of cancer recurrence (Bombard et al., 2015). 
However, translation of genomic discoveries into healthcare is not uniform and depends partly 
on evaluation of evidence regarding benefits to patient outcomes from application of genomic 
information by health care providers (Evans & Khoury, 2013).  
The field of pharmacogenetics, the study of genetic influence on both pharmacokinetics 
and pharmadynamics, will continue to be a high-impact area for precision medicine. Individuals 
from ethnically diverse populations, such as African Americans, may particularly benefit from 
precision medicine discoveries in pharmacogenetics. For example, the use of certain 
medications such as calcineurin inhibitors following organ transplantation may not achieve 
therapeutic levels in African Americans (Khush et al., 2015). Thus, healthcare providers, 
including APRNs must integrate new knowledge of known genetic polymorphism into their care 
related to “high metabolizer” status that is more common in African Americans (Beermann, Ellis, 
Sudan, & Harris, 2014; Dirks, Huth, Yates, & Meibohm, 2004). 
In addition, variability in drug response may not be solely due to the high metabolizer 
status but may be influenced by other underlying differences in biology (Giarelli, 2015; Laftavi et 
al., 2013; Mehra, Uber, Scott, & Park, 2002). Inability to detect and interpret the influence of 
genetic variants on drug response, including common polymorphisms in the cytochrome P450 
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(CYP) isoforms that contribute to differences in drug metabolism, could lead to a patient being 
incorrectly labeled as noncompliant with medication instructions (Mehra et al., 2002). Therefore, 
using genomic data in healthcare requires more than genomic discoveries. It also requires 
addressing how these discoveries contribute to health outcomes for individual patients and 
implementation of this knowledge across diverse populations and healthcare settings. The 
Institute of Medicine (IOM) Roundtable on Translating Genomic-Based Research for Health 
highlights challenges and approaches to address issues of research based evidence, health 
provider education, and health systems capacities relevant to precision medicine (IOM 2014, 
2015a, 2015b), while others (Williams & Cashion, in press; Williams, Cashion, & Veenstra, 
2015) identify unique contributions of nursing to address current and future genomic challenges.  
This paper emphasizes the increase in and emerging importance of APRN and nurse 
scientist engagement in discoveries and implementation of genomics in healthcare. Four critical 
areas for action are identified. These are: 1) bolstering genomic focused APRN practice, 
research and education efforts; 2) deriving new knowledge about disease biology, risk 
assessment, treatment efficacy, drug safety and self-management; 3) improving use of 
resources and systems that combine genomic information with other healthcare data; and 4) 
advocating for patient and family benefits and equitable access to genomic healthcare 
resources.  
Take Away Messages 
The key take away messages for each area are identified here. First, nursing leaders 
who provide graduate and continuing education for APRNs can build in genomic knowledge and 
skills, based on APRN competencies, to conduct appropriate assessments and clinical 
decisions for specific patient populations. These assessments include not only assessments of 
genomic related risk factors but also issues pertinent to the patient or family that will affect how 
well the patient and family can manage the condition within the treatment plan.  
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Second, discovery of new knowledge to inform the development of precision medicine 
will require nurse scientists to lead teams in newly developing scientific fields, particularly in 
methods for designing and conducting implementation research with diverse populations. This 
will also entail expertise in analysis and interpretation of data spanning across individual genetic 
tests to genomic sequencing. 
Third, nursing leadership within health care institutions and at the national level is 
necessary to inform the development of information systems that have the capacity to organize, 
store, and share increasingly larger amounts of omic-based data. Integration of genomic tools 
within electronic health records is needed to monitor genomic discoveries and update findings 
that are relevant to clinical practice and further research inquiry that is possible through 
precision medicine. These advancements must be balanced by adhering to patient privacy and 
preference regarding use of personal health and medical data.  
Fourth, the practice of APRNs is historically rooted in ensuring equitable delivery of 
healthcare for underserved individuals and families. Through expertise in recognizing how 
socioeconomic and cultural circumstances influence health and decision-making, APRNs are in 
an ideal position to demonstrate leadership in advocating for individualized genomic health care 
that does not limit potential access to and benefits from precision medicine. Nurses at all levels 
of education can play an influential role in informing legislators and healthcare organizations as 
well as developing policy measures to ensure that genomic healthcare is accessible to all. 
APRN Genomic Competency 
APRNs apply genomic knowledge in risk assessment, patient education, genetic testing 
and interpretation, and clinical patient management (Greco, Tinley, & Seibert, 2012; Seibert, 
2014). However, APRNs and other healthcare providers who had minimal training in genomics 
during their basic professional education often lack the knowledge to apply clinically meaningful 
findings from genomic science to individual patients and families. APRNs who lack the 
knowledge to understand the application of pharmacogenomics within the complex area of 
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patient care risk missing opportunities to use genomic discoveries, optimize patients’ 
healthcare, promote patient understanding and facilitate patient/provider engagement. IOM 
reports (IOM, 2014, 2015a) document the need for ongoing inter-professional genomics 
education and resources that support clinical decisions in order that healthcare providers and 
consumers benefit from translation of genomic discoveries into clinical care. The IOM workshop 
on interprofessional genomic education highlighted the accomplishments in APRN education 
from the viewpoints of faculty and APRN student (IOM, 2015b). A consensus panel identified 
essential genetic and genomic competencies required to provide competent APRN nursing care 
(Greco et al., 2012). Genetic and genomic knowledge that APRNs are expected to incorporate 
within their practice includes understanding of genetic and genomic influences on health; 
recommendations for screening, prevention, and treatment choices; assessing and conducting a 
critical evaluation of genetic, environmental, and epigenetic influences and risks within health 
and physical assessments; assessing client knowledge, perceptions, and responses to genetic 
and genomic information; and incorporating genetic and genomic assessment information within 
the plan of care. 
In order to achieve the maximum benefits from genomic discoveries, education of the 
APRN healthcare workforce must be faster than the rate at which genomic information is 
coming into healthcare. The American Nurses Credentialing Center (ANCC) certification in 
Advanced Genetics Nursing is one new mechanism for documenting genomic competencies. 
Nurses in the United States and worldwide, who demonstrate genomic skills, knowledge, and 
abilities, have a minimum of 1500 practice hours in a genomic specialty in the past 5 years, and 
minimum of 30 hours of continuing education in advanced genetic and genomic topics in the 
past 3 years are eligible to submit a portfolio for expert peer review and certification (AANC, 
2015) (www.nursecredentialing.org).  
Genetic and genomic competencies and continuing education opportunities are 
important for preparing educators and clinicians to use this information in healthcare, and 
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APRNs must be aware of how these discoveries contribute to health outcomes for individual 
patients and families. Examples of the necessity of current knowledge of genomic aspects of 
health are in APRN practice in sports medicine, primary care, and cardiovascular specialty 
practices. Genomic evidence-based guidelines have been developed for hypertrophic 
cardiomyopathy (HCM), which is characterized by a thickening of the heart and if unrecognized 
and untreated is a leading cause of sudden cardiac death in young asymptomatic individuals. 
Cascade screening of other family members who otherwise may remain silently at risk is also 
possible (Musunuru et al., 2015). This type of targeted, high-yield approach to genomic-based 
screening of individuals recognized by an APRN as being at risk for HCM because of symptoms 
and findings on a clincial exam could improve early detection and treatment of this potentially 
fatal condition.  
New Knowledge of Genomic Aspects of Precision Medicine 
Nurse scientists engage in research that informs precision medicine on multiple fronts, 
including but not limited to symptom science, health promotion and wellness, self-management, 
and end-of-life and palliative care (National Institute of Nursing Research [NINR], 2011). More 
specifically, nurse scientists investigate complex symptoms or clusters, clarify and standardize 
how these symptoms can be measured, identify biomarkers, and develop treatments and 
interventions related to symptoms of illnesses, injuries and conditions (NINR, 2015).  
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) working 
group (supported by the Centers for Disease Control and Prevention’s Office of Public Health 
Genomics) systematically reviews evidence on genomic applications in clinical practice and 
produces recommendations regarding their use (EGAPP, 2014). A comprehensive family history 
and cascade screening provide important evidence to guide the selection of treatment 
approaches for a growing number of conditions with Tier 1 genetic applications (see Table 1). 
Resources to guide clinical decisions for all conditions with significant genetic components have 
10 
 
not yet been developed and evidence to support testing to identify risk for, diagnose, and/or 
manage some symptoms or diseases remain to be developed (IOM, 2014).  
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Table 1. Tier 1 Applications for three genetic conditions* 
 
Condition Disease Characteristics  
and Prevalence 
Biomarke
rs 
Management Recommendations 
Familial 
hypercholesterolemi
a (FH), 
heterozygous 
(HeFH) and 
homozygous 
(HoFH) 
Severely elevated Low-density 
lipoprotein (LDL) cholesterol 
(LDL-C) levels  
HeFH: 20-fold increase in risk for 
coronary heart disease 
Untreated men have 50 % risk for a 
coronary event by age 50 years; 
Untreated women have 30 % risk by 
age 60 years 
HoFH: Severe coronary heart disease 
by mid-20s 
 
Prevalence of HeFH: 1:200–500 
individuals 
Prevalence of HoFH: 1:160,000–
1,000,000 individuals 
Prevalence varies in specific 
populations  
APOB, 
LDLR, and 
PCSK9 
The goal of treatment is a reduction greater than 50% in 
LDL-C concentration from baseline either with a high-
intensity statin, or ezetimibe monotherapy or a combination 
of both.  
 
For details see National Institute for Healthcare 
Excellence (NICE), Identification 
and management of familial 
hypercholesterolaemia, 2008 
https://www.nice.org.uk/guidance/CG71/chapter/1-Guidance  
Hereditary Breast 
and Ovarian Cancer 
(HBOC) 
Increased risk for breast, ovarian, 
prostate, pancreas, and skin cancer 
(melanoma)  
Lifetime risk for breast cancer 40–80 %, 
often seen by age 50 years 
Lifetime risk for ovarian cancer 11–17 
% generally seen at age 30 years or 
older 
Male breast cancer 1–10 % 
Prostate cancer Up to 39 % 
Pancreatic cancer 1–7 % 
 
Prevalence 1:300–500 individuals 
BRCA1, 
BRCA2 
Additional 
markers 
include 
PTEN, 
p53, 
Chek2, 
STK11, 
CDH1 
Use family history screening tools to identify women with an 
increased risk for harmful mutations. Those with positive 
screening results should receive genetic counseling and if 
indicated testing. Interventions that may reduce risk for 
cancer in BRCA mutation carriers include: earlier, more 
frequent, or intensive cancer screening; use of selective 
estrogen receptor modulators as risk-reducing medications 
(e.g., example, tamoxifen or raloxifene); and risk-reducing 
surgery (for example, mastectomy and/or salpingo-
oophorectomy).  
For details see US Preventive Services Task Force 
(USPSTF), Risk Assessment, Genetic Counseling, 
and Genetic Testing for BRCA-RelatedCancer in Women, 
2013 
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Prevalence varies in specific 
populations  
http://www.uspreventiveservicestaskforce.org/Page/Topic/re
commendation-summary/brca-related-cancer-risk-
assessment-genetic-counseling-and-genetic-testing 
 
National Cancer Institute (2014a). BRCA1 and BRCA2: 
Cancer Risk and Genetic Testing. Retrieved from 
http://www.cancer.gov/about-cancer/causes-
prevention/genetics/brca-fact-sheet 
 
National Cancer Institute (2014b). Genetics of Breast and 
Ovarian 
Cancer (PDQ®). Retrieved from 
http://www.cancer.gov/types/breast/hp/breast-ovarian-
genetics-pdq 
Lynch Syndrome 
(LS) 
Increased risk for colon, endometrium, 
ovarian, stomach, small intestine, 
hepatobillary tract, urinary tract, brain 
and 
skin cancers  
 
Lifetime risk for colorectal cancer 52–
82%,  
Mean age of diagnosis 44–61 years 
Lifetime risk for endometrial cancer 25–
60%, Mean age of diagnosis 48–62 
years 
Lifetime risk for gastric cancer 6–13%, 
Mean age of diagnosis 56 years 
Lifetime risk for ovarian cancer 4–12%, 
Mean age of diagnosis 42.5 years, with 
~30% diagnosed before age 40 years 
 
Prevalence 1:370–440 individuals 
Mismatch 
repair 
(MMR) 
genes: 
MLH1, 
MSH2, 
MSH6, 
PMS2, 
EPCAM 
Cascade genetic testing in newly diagnosed individuals with 
colorectal cancer aimed at reducing morbidity and mortality 
from Lynch syndrome in high-risk relatives, EGAPP Working 
Group 2009  
 
National Comprehensive Cancer Network (NCCN), 
Genetic/Familial High-Risk Assessment: Colorectal, 2014 
Evaluation of Genomic Applications in Practice and 
Prevention (EGAPP™) 
http://www.tri-
kobe.org/nccn/guideline/colorectal/english/colorectal_screen
ing.pdf 
 
 
*Adapted from George, R., Kovak, K., & Cox, S. L. (2015). Aligning policy to promote cascade genetic screening for prevention and early 
diagnosis of heritable diseases. Journal of Genetic Counseling, 24, 388–399. DOI 10.1007/s10897-014-9805-5 
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Nursing science contributes to the understanding of genomic aspects of prevention, 
diagnosis, improved clinical care, and health outcomes in individuals and families (Calzone et 
al., 2010; Genomic Nursing State of the Science Advisory Panel, 2013; NINR, 2011). As more 
people live longer with chronic disease and associated adverse symptoms, genomic science 
can help elucidate the mechanisms of symptom variability across stages of disease. This area 
of nursing research has led to the development and delivery of tailored symptom management 
interventions and may help patients make informed decisions regarding optimal selection of 
treatments and better quality of life, for example in self-regulation of exercise in children with 
cystic fibrosis (Higgins et al., 2013), or monitoring of pain in children and teens with sickle cell 
disease (Jacob, Duran, Stinson, Lewis, & Zeltzer, 2013). The Council for the Advancement of 
Nursing Science (CANS) emphasizes the importance of in-depth knowledge of biologic and 
behavioral science content, including -omics sciences, as priorities in preparation of PhD 
prepared nursing scientists (Henly et al., 2015). Resources that include omics educational 
opportunities, funding and research resources, and collaborative and interdisciplinary research 
opportunities are imperative for sustaining genomic nursing research activities that contribute to 
the evidence for precision medicine and improved health outcomes.  
Resources and Systems Capacity 
Implementation of genomic data for improving clinical care will require changes in the 
healthcare system, including how data are documented and used in existing databases, e.g., 
state cancer registries, electronic health records, etc. Nurses are key stakeholders in shaping 
healthcare institution policy regarding collection and use of health information and meaningfully 
recorded data by all members of the healthcare team (Katapodi et al., 2013). Capacities to 
store, protect, manage, and share data are being developed, although several scalability, 
privacy, security, and informed consent issues need to be resolved for data sharing in existing 
databases (IOM, 2015b).  
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Health and medical information currently stored in these databases, and future 
databases can be critical resources for both practice and research. The cycle that connects 
scientific discoveries, application in practice, and evaluation of this application leading to 
revisiting or pursuing new scientific questions will require databases that contain information 
that is standardized, comprehensive, and within systems that are flexible in responding to 
emerging needs.  
Nurses can use opportunities to shape institutional policies regarding healthcare 
knowledge systems and have the capacity to participate in “big data science” while at the same 
time advocating for ethical and societal issues in data sharing. For example, hospital routine 
data offer potentially important opportunities in terms of genomic and healthcare research 
because they are available for all patients, can be obtained with an acceptable cost, and could 
provide standardized information. However, combining genomic with other health data to derive 
new knowledge about disease biology, treatment efficacy, and drug safety presents several 
challenges. The healthcare system is largely unprepared to handle large-scale information that 
is readily available, for example in electronic health records or International Classification of 
Diseases (ICD) diagnoses. Nurses can take leadership roles in creating and evaluating 
mechanisms to promote “big data science” that also serves specific patient, ethnic, or cultural 
populations (Bakken, Stone, & Larson, 2008; Clancy et al., 2014). 
Advocate for Patient and Family Benefits 
Benefits from clinical genetic and genomic discoveries may be especially inaccessible to 
healthcare consumers who have limited education and financial resources, live in areas where it 
is difficult to access genetic specialists, or belong to underserved populations who experience 
healthcare disparities (Jones, Katapodi, & Lockhart, 2015; Katapodi, Northouse, Milliron, Liu, & 
Merajver, 2013). The promise of scientific advancement that promotes health for everyone, as 
articulated in the Precision Medicine Initiative, includes the premise that patients and those who 
interact with the healthcare system not only will benefit from scientific advances but will also 
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have the opportunity to form true partnerships with the scientific community to engage in 
research and shape agendas.  
This is best illustrated in a case of a college freshman who conducted a genomic 
analysis of her own cancer, used social media to mobilize others with this cancer in order to 
“liberate their samples from hospitals where they had their surgery”, and set up clinical trials 
(Terry, 2015, p. 113). It also means that people feel comfortable sharing their own health data, 
which would lead to mining the data for new information that can be tested and translated back 
into healthcare (Terry, 2015).  
However, the benefits of genomic research for all populations will be limited if fear of 
discrimination prevents individuals from participating in translational research studies that 
explore potential real life consequences of using information resulting from genome sequencing 
(Green, Lautenbach,& McGuire, 2015). Resources for patient education, advocacy for the 
underserved, appropriate fit of genomic health information with individual, family, and 
community preference, and genomic healthcare services that are culturally appropriate and 
sensitive to varying genomic literacy levels have yet to be a reality. 
Recommendations 
The following policy and research opportunities that address one or more of the issues in this 
paper are identified, as well as steps that nurses can engage in to enhance personalized 
nursing care for improving genomic healthcare for all individuals: 
1. Incorporate and expand genomic education for APRNs as appropriate to support 
precision medicine and personalized genomic health at all levels of care, across the 
lifespan and within all practice settings. 
2. Endorse CANS Idea Festival proposal to focus PhD training for nurse scientists to 
enable translation of discovery into practice. 
3. Expand doctoral training for nurse scientists and clinicians to prepare an ethnically 
diverse nursing workforce prepared to implement genomics based health care.  
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4. Increase nursing research emphases on promoting health of individuals and families in a 
wide variety of clinical care and research settings based on personalized genomic health 
information. 
5. Create and evaluate easy to use accessible (i.e., web-based) genomic clinical decision 
resources and enable access to these resources by APRNs and other healthcare 
providers across diverse health care settings. 
6. Create and evaluate genomic health literacy resources for members of the public that 
are appropriate for diverse socioeconomic, educational, health literacy, or cultural 
backgrounds. 
7. Actively participate in international, national and institutional committees that formulate 
policies regarding healthcare knowledge systems. 
8. Advocate for recruitment, consent, and access to personal genomic health information 
that is consistent with each person’s preferences. 
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